Canaccord reiterates a Sell on Seattle Genetics (SGEN -3.2%) after its unwillingness to provide...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Canaccord reiterates a Sell on Seattle Genetics (SGEN -3.2%) after its unwillingness to provide 2012 sales guidance for Adcetris in tandem with its Q4 report spooks investors. The firm sees "a number of factors" hurting Adcetris sales this year, including sales adjustments, the near-exhaustion of a patient pool treated last year, and the negative impact on treatment duration from a change in treatment approach.